A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Capecitabine; Docetaxel; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 May 2010 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 26 May 2010 Planned end date changed from 1 Mar 2012 to 1 Mar 2010 as reported by ClinicalTrials.gov.